PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer
-
Published:2024-11
Issue:
Volume:180
Page:111711
-
ISSN:0720-048X
-
Container-title:European Journal of Radiology
-
language:en
-
Short-container-title:European Journal of Radiology
Author:
Yadav Divya,
Dutruel Silvina P.,
O’Dwyer Elisabeth,
Ricaurte-Fajardo Andres,
Upadhyay Rituraj,
Palmer Joshua D.,
Pannullo Susan C.,
Tagawa Scott T.,
Knisely Jonathan P.S.,
Brandmaier Andrew,
Osborne Joseph R.,
Ivanidze JanaORCID
Reference32 articles.
1. PSMA PET-CT in the diagnosis and staging of prostate cancer;Combes;Diagnostics,2022
2. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial;Calais;Lancet Oncol.,2019
3. 18F-fluciclovine versus PSMA PET imaging in primary tumor detection during initial staging of high-risk prostate cancer: a systematic review and meta-analysis;Yadav;Radiol. Imaging Cancer,2022
4. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer;Pepe;Arch. Ital. Urol. Androl. Organo Uff. Soc. Ital. Ecogr. Urol. E Nefrol.,2022
5. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study;Hofman;Lancet Oncol.,2018